Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "ED"

7609 News Found

Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr
News | November 07, 2024

Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr

Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024


KIMS to acquire 3,000 beds in next 5 years in Kerala
Healthcare | November 07, 2024

KIMS to acquire 3,000 beds in next 5 years in Kerala

The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode


Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr
News | November 06, 2024

Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024


Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility
News | November 06, 2024

Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities


Imtiyaz Basade appointed Senior VP of NATCO Pharma
People | November 05, 2024

Imtiyaz Basade appointed Senior VP of NATCO Pharma

He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.


Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr
News | November 05, 2024

Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr

The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024


Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
News | November 05, 2024

Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies


USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
Drug Approval | November 02, 2024

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature